Value
5.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 9.0 |
CBIO · Why this verdict
Why Crescent Biopharma (CBIO) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.7/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Crescent Biopharma offers an asymmetric risk/reward setup and an oversold technical pullback that the engine flags as a buying opportunity, but notable insider selling, a below-floor risk score, and a history of earnings misses keep the setup speculative and risk-heavy.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The engine's risk/reward setup shows a favorable 3.9x asymmetry ratio, with 57.8% upside to target against a much smaller downside, clearing the asymmetry threshold with room to spare. Engine gate (passed) | The asymmetry ratio should stay above 2x and upside potential should remain above 40% over the next 12 months if the setup holds. | →Stable |
| CounterA high asymmetry ratio in a speculative biotech can evaporate quickly on binary trial or regulatory news, since the downside estimate assumes an orderly stop-loss rather than a gap move. | ||
RSI at 39 reflects an uptrend pullback that the engine flags as a buy opportunity, even though falling on-balance volume kept the momentum score at 3.6, below the engine's 4.5 threshold. Momentum breakdown | RSI should recover back above 50 and momentum score should climb back above 4.5 within the next 1-2 months if the pullback resolves higher. | ↑Improving |
| CounterAn RSI pullback within a broader downtrend can just as easily continue lower, especially given the high short interest already pressuring the stock. | ||
Insiders have been net sellers, offloading $1,226,126 (0.26% of market cap) across 7 sell transactions in the past 90 days with zero buys, producing a bearish insider signal. Insider | Insider selling should slow to fewer than 3 transactions per quarter and net value sold should fall below $500,000 if confidence is stabilizing. | →Stable |
| CounterRoutine pre-scheduled selling plans (Rule 10b5-1) by executives diversifying compensation can look identical to a bearish signal without reflecting any change in company outlook. | ||
The company has missed or come in-line on 3 of its last 4 earnings reports, with an average surprise of -12.1%, reflecting inconsistent execution against estimates. Earnings | The beat rate should improve to at least 3 of 4 with average surprise turning positive over the next 4 reported quarters. | ↑Improving |
| CounterFor a clinical-stage biotech, EPS surprises are dominated by R&D spending timing rather than commercial execution, so the beat/miss pattern may not be a meaningful signal. | ||
The engine's risk/reward setup shows a favorable 3.9x asymmetry ratio, with 57.8% upside to target against a much smaller downside, clearing the asymmetry threshold with room to spare.
→StableEngine gate (passed)
- Expectation
- The asymmetry ratio should stay above 2x and upside potential should remain above 40% over the next 12 months if the setup holds.
CounterA high asymmetry ratio in a speculative biotech can evaporate quickly on binary trial or regulatory news, since the downside estimate assumes an orderly stop-loss rather than a gap move.
RSI at 39 reflects an uptrend pullback that the engine flags as a buy opportunity, even though falling on-balance volume kept the momentum score at 3.6, below the engine's 4.5 threshold.
↑ImprovingMomentum breakdown
- Expectation
- RSI should recover back above 50 and momentum score should climb back above 4.5 within the next 1-2 months if the pullback resolves higher.
CounterAn RSI pullback within a broader downtrend can just as easily continue lower, especially given the high short interest already pressuring the stock.
Insiders have been net sellers, offloading $1,226,126 (0.26% of market cap) across 7 sell transactions in the past 90 days with zero buys, producing a bearish insider signal.
→StableInsider
- Expectation
- Insider selling should slow to fewer than 3 transactions per quarter and net value sold should fall below $500,000 if confidence is stabilizing.
CounterRoutine pre-scheduled selling plans (Rule 10b5-1) by executives diversifying compensation can look identical to a bearish signal without reflecting any change in company outlook.
The company has missed or come in-line on 3 of its last 4 earnings reports, with an average surprise of -12.1%, reflecting inconsistent execution against estimates.
↑ImprovingEarnings
- Expectation
- The beat rate should improve to at least 3 of 4 with average surprise turning positive over the next 4 reported quarters.
CounterFor a clinical-stage biotech, EPS surprises are dominated by R&D spending timing rather than commercial execution, so the beat/miss pattern may not be a meaningful signal.
Per-dimension breakdown
Quality
6.0/10data confidence 71%| Component | Sub-score |
|---|---|
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 7.0 |
| Piotroski F | 7.8 |
- ▸Strong Piotroski F-Score: 7/9
Growth
5.0/10data confidence 50%Momentum
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 3.0 |
| OBV | 1.0 |
| MA position | 4.0 |
| Volume | 6.7 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 3.0 |
| Analyst rating | 7.3 |
| Price target | 9.9 |
- ▸LLM news sentiment: -0.40 (n=1)
- ▸Light analyst coverage (5.0) — signal dampened
- ▸Analyst upside: 86%
Insider
2.5/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
- ▸Notable insider selling — $1,226,126 (0.228% of mkt cap)
Peer rank
4.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.2 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 5.1 |
| support resistance | 5.4 |
| 52w position | 2.1 |
| gap | 3.0 |
- ▸Extreme gap up (8.8%) - may pull back
Risk (lower is worse)
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.0 |
| days to cover | 0.0 |
| volatility | 0.0 |
| debt equity | 10.0 |
| news risk | 6.0 |
- ▸High short interest: 30%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
2.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Earnings concerns: 1B/2M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- ASYMMETRY:4.1>=1.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:4.0<4.5
Warning (1)
- INSIDER:0.23%=MODERATE
Reward-to-Risk
4.14
Upside
+62.1%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 41 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The F-path SELL output fired on the hard insider floor: insider score of 2.5 sits below the 3.0 threshold (heavy insider selling), which triggers SELL regardless of other dimensions. Co-occurring failed gates ( MOMENTUM:4.0<4.5) reinforce the read. Current asymmetry R:R is 4.14 — supplementary context, not the trigger for this path.
The strongest dimensions are Sentiment at 6.7, Quality at 6.0, and Value at 5.4; the weakest are Insider at 2.5, Catalyst at 2.8, and Risk (lower is worse) at 3.2. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 4.14 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Asymmetric Upside Reward Setup
Trip ifAsymmetry ratio falls below 1.5.
- P2Oversold Pullback Opportunity
Trip ifRSI falls below 30 while price declines more than 10% over the next month.
- P3Notable Insider Selling Signal
Trip ifNet insider selling exceeds $2,000,000 over the next 90 days.
- P4Earnings Miss History Risk
Trip ifAverage earnings surprise stays below -10% for 2 more consecutive quarters.